Global Transmucosal Drug Delivery Systems Market Size & Trends Report Segmented by Route of Administration (Buccal, Nasal, Ocular), Dosage Form (Tablets, Sprays, Gels), Drug Type (Small Molecules, Biologics), End User & Regional Forecast to 2031

Transmucosal drug delivery systems provide a means of delivering drugs through mucous membranes including sub-lingual, buccal, nasal, ocular, rectal, vaginal, and pulmonary among others. The advantage of transmucosal drug delivery systems is fast response time associated with local systemic action and the ability to avoid ruining drugs due to GI tract breakdown i.e., first pass metabolism, thereby improving bioavailability of many drug products and/or increasing delivery speed for some drugs. Types of transmucosal drug delivery include, oral films, sprays, tablets, gels, patches, suppositories, and inserts among others. Key market applications include hormone replacement therapy, acute pain, chronic pain, infectious disease, neurological disorders, cardiovascular diseases, diabetes mellitus, and cancer, among others. Growth is driven by demand for non-invasive, patient-friendly, and self-administered drug delivery solutions.

Growing demand for non-invasive drug delivery to propel market demand

One of the main driving forces behind the transmucosal drug delivery systems market is the increase in demand from both patients and healthcare providers for non-invasive alternatives to injection-based medications or procedures. This increasing demand is driving the use of trans-mucosal delivery routes that offer patients with pain-free, easy-to-use options that promote greater comfort and treatment compliance. Transmucosal drug delivery systems are particularly helpful for pediatric, geriatric, or needle-phobic patients as well as for those requiring frequent or long-term medication.  Since many transmucosal drugs bypass gastrointestinal degradation and first-pass hepatic metabolism, they are absorbed more quickly into the body and have a higher bioavailability than most traditional oral medications.

Home healthcare and self-administration are helping to spur the demand for easy-to-use transmucosal drugs, such as oral thin films, nasal sprays, and fast-dissolving tablets. With an emphasis on patient-centric care from healthcare systems and the continued innovation from pharmaceutical companies to provide non-invasive drug delivery formulations, there is still increased adoption of trans-mucosal drug delivery technology in the various therapeutic areas and continuing growth of the market.

To learn more about this report, download the PDF brochure

Faster therapeutic onset compared with conventional oral formulations is fueling the demand for transmucosal drug delivery systems

A key contributing factor to the increasing growth of the transmucosal drug delivery systems market is the therapeutic onset compared with conventional oral formulations. Drugs administered through buccal, sublingual, nasal, and other transmucosal delivery methods are quickly absorbed into systemic circulation from highly vascular mucosal tissue. Because transmucosal delivery routes bypass the gastrointestinal degradation and first-pass hepatic metabolism of a drug administered orally, the therapeutic effects from using transmucosal delivery routes occur quicker than with traditional oral drugs. Examples of conditions where immediate symptom relief is needed and expanding the market for transmucosal delivery include acute pain, migraine headache, epilepsy, opioid overdose, allergy, angina, and breakthrough cancer pain.

Additionally, the faster absorption of drugs using transmucosal routes leads to better health outcomes while providing patients with timely symptom relief. Pharmaceutical companies are not only responding to the need for quickly acting transmucosal formulations to address unmet clinical needs, but also creating fast-acting formulations to meet the increasing demand for therapies with immediate and predictable therapeutic effects, thereby increasing the rate of acceptance of the use of transmucosal drug delivery systems by healthcare providers in acute and chronic care settings resulting in accelerated market growth.

To learn more about this report, download the PDF brochure

Route of Administration Segment Outlook

The buccal segment accounts for the largest share of the transmucosal drug delivery systems market. This can be attributed to the fact that buccal delivery methods are commonly used for administering drugs that require rapid systemic absorption while avoiding first-pass hepatic metabolism. Examples of buccal formulations include buccal tablets, buccal films, buccal lozenges, and buccal patches, each of which provides extended contact time with the mucosa, improves bioavailability, requires minimal trauma to the oral cavity, and offers high patient compliance. The various applications of buccal products include pain management, hormone replacement therapy, smoking cessation, and cardiovascular diseases.

On the other hand, the nasal segment is expected to register the fastest growth rate during the forecast period. The increasing demand for needle-free, rapidly absorbing drug delivery methods and direct nose-to-brain drug delivery is driving rapid adoption of intranasal formulations. Additionally, growing development of nasal vaccines, biologics, peptide therapies, and emergency rescue medications, along with continued advancements in nasal spray devices and permeation enhancers, is expected to support robust growth of the nasal segment throughout the forecast period.

Regional Outlook: Advanced healthcare infrastructure and strong pharmaceutical innovation drive North American market leadership

North America is the largest regional market for transmucosal drug delivery system due to a combination of factors including the region's well-developed health care system; large pharmaceutical and biotech companies; and higher adoption of innovative drug delivery technologies in this market. Furthermore, North America is seeing high investments into research and development, has favorable reimbursement policies, and has presence of many leading pharmaceutical companies developing transmucosal medications for chronic pain treatment, treating neurological disorders, hormone replacement therapy, and for emergency use. The large number of people suffering from chronic diseases in North America, the growing demand for patient-friendly methods for delivering medicine, and the faster approval of new, novel therapies from regulatory bodies all support the growth of this market.

On the other hand, the Asia Pacific region is projected to be the fastest-growing market for these products over the forecast period, driven primarily by the rapid growth of health care systems; increasing rates of health care spending; the rising prevalence of chronic illnesses; and better access to innovative treatments across countries like China, India, and Japan. Additionally, large investments into pharmaceutical manufacturing in this region along with a steady increase in clinical studies and government support of self-administered non-invasive methods of delivering drugs will help spur this market further within the Asia Pacific region.

Competitive Landscape Analysis

The global transmucosal drug delivery systems market is marked by the presence of established and emerging market players such as

• Pfizer Inc. (US)
• GSK plc (UK)
• Johnson & Johnson (US)
• Novartis AG (Switzerland)
• AstraZeneca (UK)
• Bayer AG (Germany)
• Hoffmann-La Roche Ltd. (Switzerland)
• Eli Lilly and Company (US)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bausch Health Companies Inc. (Canada)

Get a sample report for competitive landscape analysis

Growth strategies adopted by players to establish their foothold in the transmucosal drug delivery systems market

Players operating in this market are adopting various growth strategies such as new product launches and approvals; acquisitions; expansions; and strategic partnerships, agreements, and collaborations, to garner market share. For instance,

• In May 2025, ALK entered a four-year co-promotion agreement with ARS Pharmaceuticals to promote neffy (epinephrine nasal spray) to up to 9,000 pediatricians across the US, expanding access to needle-free treatment for anaphylaxis. The partnership combines ALK's dedicated pediatric sales force with ARS Pharma's marketing efforts to accelerate neffy adoption and strengthen both companies' presence in the US allergy treatment market
• In November 2023, Hovione expanded its nasal drug delivery capabilities through a partnership with IDC to develop innovative single-use and multidose nasal powder delivery devices for local, systemic, and nose-to-brain drug delivery. The collaboration strengthens Hovione's integrated CDMO offering by combining formulation, manufacturing, and device technologies to accelerate commercialization of intranasal therapies

Report Scope

Global Transmucosal Drug Delivery Systems Market Segmentation

This report by Medi-Tech Insights provides the size of the global transmucosal drug delivery systems market at the regional and country-level from 2024 to 2031. The report further segments the market by route of administration, dosage form, drug type, application, and end user.

Market Size & Forecast (2024-2031), By Route of Administration, USD Billion

• Buccal
• Sublingual
• Nasal
• Ocular
• Vaginal
• Rectal
• Pulmonary
• Other Routes of Administration

Market Size & Forecast (2024-2031), By Dosage Form, USD Billion

• Tablets
• Oral Thin Films & Wafers
• Sprays
• Gels
• Lozenges
• Patches
• Suppositories
• Inserts
• Powders
• Other Dosage Forms

Market Size & Forecast (2024-2031), By Drug Type, USD Billion

• Small Molecules
• Biologics
• Vaccines
• Other Drug Types

Market Size & Forecast (2024-2031), By Application, USD Billion

• Pain Management
• Hormone Replacement Therapy
• Central Nervous System Disorders
• Cardiovascular Diseases
• Diabetes
• Infectious Diseases
• Oncology
• Other Applications

Market Size & Forecast (2024-2031), By End User, USD Billion

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers (ASCs)
• Home Care Settings
• Other End Users

Market Size & Forecast (2024-2031), By Region, USD Billion

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Related Reports:

Global Nanoparticle Drug Delivery Systems Market Size Share, Growth and Trends Report Segmented by Type (LNP, Polymeric, Inorganic), Modality (Small Molecule, Biologics, CGT), Application (Oncology, CVDs), End-user Analysis, & Regional Forecast to 2031

Global Polymer-based Drug Delivery Systems Market Size & Trends Report Segmented by Route of Administration (Oral, Injectable, Transdermal, Topical), Polymer Type (Natural, Synthetic), Drug Type (Small Molecules, Biologics), End User & Regional Forecast to 2031